We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE) (SCATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01531387
Recruitment Status : Terminated (inability to reach a satisfactory endpoint with respect to adequate recruitment)
First Posted : February 13, 2012
Results First Posted : December 9, 2015
Last Update Posted : February 8, 2016
Information provided by (Responsible Party):

February 6, 2012
February 13, 2012
June 19, 2015
December 9, 2015
February 8, 2016
May 2012
January 2014   (Final data collection date for primary outcome measure)
Conversion to Abnormal Maximum TAMV [ Time Frame: 30 months ]
The primary endpoint of the SCATE trial is the cumulative incidence of conversion to abnormal maximum TAMV (time-averaged mean velocity) measured by transcranial doppler (TCD) ultrasonography. Subjects must have conditional velocities at baseline, defined as 170 - 199 cm/sec, which indicate moderate stroke risk. Abnormal velocities are defined as ≥ 200 cm/sec, which indicate high stroke risk. The number of conversions from conditional velocities to abnormal velocities in each treatment arm will be compared as the primary outcome.
Same as current
Complete list of historical versions of study NCT01531387 on ClinicalTrials.gov Archive Site
  • Serial TCD Velocities [ Time Frame: 30 months ]
    This secondary outcome measure will be the highest TAMV obtained in specific arteries. Serial TCD velocities are measured throughout the SCATE trial and will be compared to the baseline value.
  • Cumulative Incidence of Neurological Events [ Time Frame: 30 months ]
    The cumulative incidence of neurological events as a secondary endpoint, which include both stroke and non-stroke neurological events, will be determined over the treatment period for both standard and alternative arms.
  • Cumulative Incidence of Non-Neurological Events [ Time Frame: 30 months ]
    The cumulative incidence of non-neurological sickle cell-related events, including vaso-occlusion and splenic sequestration, will be estimated over the treatment period for both standard and alternative arms.
  • Quality of Life [ Time Frame: 30 months ]
    Standard Quality of Life measure will be taken during specific time points, as well as one newly-developed Sickle Cell Disease Quality of Life measure.
Same as current
Not Provided
Not Provided
Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)
Sparing Conversion to Abnormal TCD Elevation (SCATE) - a Phase III Clinical Trial to Compare Standard Care (Observation) With Alternative Therapy (Hydroxyurea) for Reducing the Risk of Converting to an Abnormal TCD Velocity in Children With Sickle Cell Anemia and Conditional Pre-treatment TCD Velocities.
The primary goal of the Phase III SCATE trial is to compare 30 months of alternative therapy (hydroxyurea) to standard care (observation) in children with sickle cell anemia and conditional (170 - 199cm/sec) Transcranial Doppler (TCD) velocities. For the alternative regimen (hydroxyurea) to be declared superior to the standard treatment regimen (observation), the hydroxyurea-treated group must have a three-fold reduction in the incidence of conversion to abnormal TCD velocities (≥ 200 cm/sec), compared to the standard treatment arm.

Results from previous studies confirm an increased risk of stroke among children with conditional TCD velocities. In addition, studies suggest that patients who were on observation alone, converted from conditional TCD (moderate risk category) to an abnormal TCD (with a much higher risk for primary stroke) within 30 months of initial identification of the conditional TCD velocity; this conversion led to initiation of chronic and indefinite transfusions in all cases. Preliminary data suggests that the risk of conversion to abnormal TCD velocities will be lower for subjects with conditional TCD velocities on hydroxyurea by at least three-fold. This important difference in conversion risk rate suggests that an alternative treatment could have a substantial and beneficial impact on patients with elevated TCD velocities.

An alternative treatment could protect the brain of patients with SCA and conditional TCD velocities who are at increased risk for stroke. The avoidance of chronic blood transfusions would be a great benefit for all children with sickle cell disease, especially those in developing countries where the blood supply may be less safe (in comparison with that in the US) or unavailable, and very costly.

Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Sickle Cell Anemia
Drug: Hydroxyurea
Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
Other Names:
  • Hydroxycarbamide
  • Hydrea
  • Droxia
  • No Intervention: Standard Therapy: Observation
    Half of the subjects will be randomized to clinical observation only, which includes monthly visits with clinical evaluations, laboratory tests, and TCD endpoint examinations
  • Experimental: Hydroxyurea
    Half of the subjects will be randomized to hydroxyurea, taken as capsules (300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Subjects will be monitored monthly with clinical evaluations, laboratory tests, and TCD endpoint examinations.
    Intervention: Drug: Hydroxyurea
Hankins JS, McCarville MB, Rankine-Mullings A, Reid ME, Lobo CL, Moura PG, Ali S, Soares DP, Aldred K, Jay DW, Aygun B, Bennett J, Kang G, Goldsmith JC, Smeltzer MP, Boyett JM, Ware RE. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial. Am J Hematol. 2015 Dec;90(12):1099-105. doi: 10.1002/ajh.24198. Epub 2015 Nov 17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
January 2014
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Pediatric subjects with severe forms of sickle cell anemia (HbSS, HbSβ0 thalassemia, HbSD, HbSOArab)
  2. Age: ≥ 2 and < 11 years of age, at the time of enrollment
  3. Conditional TCD Velocity (170 - 199cm/sec) by Transcranial Doppler ultrasonography examination within 3 months of enrollment
  4. Parent or guardian willing and able to provide informed consent
  5. Ability to comply with study related treatments, evaluations, and follow-up

Exclusion Criteria:

  1. Prior abnormal TCD Velocity
  2. History of clinical stroke
  3. Inability to take or tolerate daily oral hydroxyurea, including

    • Known allergy to hydroxyurea therapy
    • Known positive serology to HIV infection
    • Known malignancy
    • Current lactation
  4. Abnormal laboratory values at initial evaluation (temporary exclusions):

    • Hemoglobin concentration < 6.0 gm/dL
    • Absolute reticulocyte count < 100 x 10^9/L with a hemoglobin concentration < 8.0 gm/dL
    • WBC count < 3.0 x 10^9/L
    • Absolute neutrophil count (ANC) < 1.0 x 10^9/L
    • Platelet count < 100 x 10^9/L
  5. Current use of therapeutic agents for sickle cell disease (e.g., hydroxyurea, arginine, decitabine, magnesium, chronic transfusions). Subjects must be off therapeutic agents for sickle cell disease for at least 3 months prior to enrollment.
  6. Current participation in other therapeutic clinical trials
  7. Serum creatinine more than twice the upper limit for age OR ≥ 1.0 mg/dL
  8. Any condition or chronic illness, which in the opinion of the clinical investigator makes participation ill-advised
  9. Pregnancy (for post-menarchal females only)
  10. Erythrocyte transfusion within the past 2 months
  11. Previous stem cell transplant or other myelosuppressive therapy
Sexes Eligible for Study: All
2 Years to 10 Years   (Child)
Contact information is only displayed when the study is recruiting subjects
Brazil,   Jamaica,   United States
H-29205 SCATE
R01HL098239 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati
  • National Heart, Lung, and Blood Institute (NHLBI)
  • St. Jude Children's Research Hospital
  • Tropical Medicine Research Institute
  • Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
Principal Investigator: Russell E. Ware, MD, PhD Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP